Jordan vs Lao People's Democratic Republic: Percentage of bloodstream infection due to Escherichia coli resistant
Jordan
57.2%
in 2022
Lao People's Democratic Republic
52.6%
in 2022
Jordan rank
15th
Lao People's Democratic Republic rank
17th
Percentage of bloodstream infection due to Escherichia coli resistant over time
- Jordan
- Lao People's Democratic Republic
How they compare
Jordan currently reports 57.2% against 52.6% in Lao People's Democratic Republic, a difference of 4.6%.
That makes Jordan's figure about 1.1 times Lao People's Democratic Republic's.
Across all 5 years both countries report, Jordan has been ahead every year.
Jordan ranks 15th and Lao People's Democratic Republic ranks 17th of 50 countries.
Jordan has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Jordan | Lao People's Democratic Republic | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 64.3% | 47.7% | 16.6% | Jordan |
| 2020s | 60.7% | 49.7% | 11.1% | Jordan |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher percentage of bloodstream infection due to escherichia coli resistant, Jordan or Lao People's Democratic Republic?
- Jordan, at 57.2% against 52.6% in Lao People's Democratic Republic as of 2022.
- What is the difference in percentage of bloodstream infection due to escherichia coli resistant between Jordan and Lao People's Democratic Republic?
- 4.6%, with Jordan ahead.
- How many years of comparable data are there for Jordan and Lao People's Democratic Republic?
- 5 years are reported by both, from 2018 to 2022.
- How do Jordan and Lao People's Democratic Republic rank globally for percentage of bloodstream infection due to escherichia coli resistant?
- Jordan ranks 15th and Lao People's Democratic Republic ranks 17th of 50 countries.
- Where does this data come from?
- United Nations Statistics Division, SDG Global Database, published as Percentage of bloodstream infection due to Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.